PORTOLA PHARMACEUTICALS INC
DelistedCIK 1269021fmd_1PGRG0WDWJP6TBC5VT4F0K7WB0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Mar 31, 2020, 35 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 36 | 23 | 40 | 117 |
| Cost of revenue | – | – | – | – | – | – | 0 | 18 | 44 |
| Gross profit | – | – | – | – | – | – | 22 | 22 | 72 |
| Research and development | 46 | 50 | 79 | 124 | 200 | 247 | 204 | 216 | 125 |
| Selling, general and administrative | – | – | 15 | 24 | 39 | 58 | 91 | 151 | 219 |
| Total operating expenses | 58 | 61 | 95 | 147 | 239 | 305 | 295 | – | – |
| Operating income | 20 | 11 | (84) | (138) | (227) | (270) | (273) | (345) | (271) |
| Interest expense | 0 | – | – | – | – | 0 | 12 | 19 | 31 |
| Other non-operating income (expense) | – | 1 | 1 | 0 | 0 | 2 | (1) | 14 | 10 |
| Income before taxes | – | – | (83) | (137) | (227) | (268) | (286) | – | – |
| Income tax expense | – | – | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (83) | (137) | (227) | (268) | (286) | – | – |
| Net income | 20 | 11 | (83) | (137) | (227) | (269) | (286) | (350) | (291) |
| Net income to common shareholders | 0 | – | (83) | (137) | – | – | – | – | – |